Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88

R. Daifuku, K. Haenftling, J. Young, E. S. Groves, C. Turrell, Frederick J Meyers

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.

Original languageEnglish (US)
Pages (from-to)2349-2351
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number10
StatePublished - 1992
Externally publishedYes

Fingerprint

Monoclonal Antibodies
Antibodies
Gram-Negative Bacteria
Antineoplastic Agents
Immunoglobulin M
Half-Life
Lipopolysaccharides
Immunoglobulin G
Body Weight
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Daifuku, R., Haenftling, K., Young, J., Groves, E. S., Turrell, C., & Meyers, F. J. (1992). Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. Antimicrobial Agents and Chemotherapy, 36(10), 2349-2351.

Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. / Daifuku, R.; Haenftling, K.; Young, J.; Groves, E. S.; Turrell, C.; Meyers, Frederick J.

In: Antimicrobial Agents and Chemotherapy, Vol. 36, No. 10, 1992, p. 2349-2351.

Research output: Contribution to journalArticle

Daifuku, R, Haenftling, K, Young, J, Groves, ES, Turrell, C & Meyers, FJ 1992, 'Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88', Antimicrobial Agents and Chemotherapy, vol. 36, no. 10, pp. 2349-2351.
Daifuku R, Haenftling K, Young J, Groves ES, Turrell C, Meyers FJ. Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. Antimicrobial Agents and Chemotherapy. 1992;36(10):2349-2351.
Daifuku, R. ; Haenftling, K. ; Young, J. ; Groves, E. S. ; Turrell, C. ; Meyers, Frederick J. / Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. In: Antimicrobial Agents and Chemotherapy. 1992 ; Vol. 36, No. 10. pp. 2349-2351.
@article{ffb6fefa6ad04d678db66171cfbe2b03,
title = "Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88",
abstract = "Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.",
author = "R. Daifuku and K. Haenftling and J. Young and Groves, {E. S.} and C. Turrell and Meyers, {Frederick J}",
year = "1992",
language = "English (US)",
volume = "36",
pages = "2349--2351",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88

AU - Daifuku, R.

AU - Haenftling, K.

AU - Young, J.

AU - Groves, E. S.

AU - Turrell, C.

AU - Meyers, Frederick J

PY - 1992

Y1 - 1992

N2 - Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.

AB - Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.

UR - http://www.scopus.com/inward/record.url?scp=0026660937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026660937&partnerID=8YFLogxK

M3 - Article

C2 - 1444318

AN - SCOPUS:0026660937

VL - 36

SP - 2349

EP - 2351

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -